Vasopressor meets vasodepressor: The AT1-B2 receptor heterodimer

Area of Science:

• Cardiovascular Pharmacology
• Molecular Cardiology
• Receptor Biology

Background:

• The angiotensin II type 1 receptor (AT1R) is a key target for cardiovascular disease treatments.
• AT1R system sensitization contributes to cardiovascular disorders, with mechanisms not fully understood.
• AT1R activation is modulated by heterodimerization with the bradykinin B2 receptor (B2R).

Purpose of the Study:

• To investigate the role of AT1-B2 receptor heterodimerization in cardiovascular pathophysiology.
• To explore the therapeutic potential of targeting the AT1-B2 receptor heterodimer.

Main Methods:

• Biophysical techniques (BRET, FRET) to confirm heterodimerization.
• Studies in transgenic mice with targeted B2R gene deletion.
• Analysis of β-arrestin-biased agonism effects on AT1R-B2R complexes.

Main Results:

• AT1-B2 receptor heterodimerization enhances AT1R signaling in hypertension models.
• AT1R-B2R heterodimers are implicated in preeclampsia pathogenesis.
• Targeted deletion of B2R reduced AT1R-stimulated vasopressor response in mice.
• A β-arrestin-biased agonist induced co-internalization of AT1R and B2R.

Conclusions:

• AT1-B2 receptor heterodimerization is a significant factor in cardiovascular disease.
• Specific targeting of the AT1-B2 receptor heterodimer offers a novel therapeutic strategy.
• This approach could lead to new drugs for pathological angiotensin II-AT1 receptor system activation.